BioXcel’s (NASDAQ:BTAI) investigational drug BXCL501 – a proprietary sublingual film of dexmedetomidine, for the treatment of acute agitation – has been granted Fast Track Designation by the FDA.
Top-line data from the Phase 1 study of the drug is expected in H1 2019.
Shares +15.35% premarket
Source: Press Release
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.